Actively Recruiting
Study of SCT800 to Prevent Bleeding in Boys Up to 6 Years Old with Severe Hemophilia A Who Have Not Had Previous Treatment
Led by Sinocelltech Ltd. · Updated on 2026-02-27
36
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SCT800, a recombinant human coagulation factor VIII, in patients with severe previously untreated Hemophilia A. Approved in China since 2021, SCT800 is used for preventing and managing bleeding events in both adults and children. This study aims to further assess the safety and effectiveness of SCT800 when used as a preventative treatment in young patients who have not received prior factor VIII treatments. Participants will receive SCT800 intravenously for prophylaxis at doses ranging from 15 to 50 IUkg. For treating bleeding events, dosing varies by severity 10-20 IUkg for mild bleeding, 15-30 IUkg for moderate bleeding, and 30-50 IUkg for severe bleeding. The study is open label and uncontrolled, focusing on previously untreated male patients with severe hemophilia A. During the study, researchers will monitor participants up to 50-100 exposure days to assess the incidence of factor VIII inhibitor development, bleeding rates, adverse events, SCT800 consumption, and its hemostatic effect. Evaluations include laboratory tests and clinical assessments to ensure safety and track treatment impact. Participation lasts through the exposure period, with ongoing monitoring to understand SCT800s effects in this population.
CONDITIONS
Brief Title
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Research Team
R
Runhui Wu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here